Cinclus Pharma: start of phase 3 reiterated for Q3'25
Cinclus Pharma reported its Q1 results which focused on balance sheet items and a recap of corporate achievements for the quarter, with a cash position at SEK523.9m and an EBIT at SEK(47.519m). With the current cash position and operational cash burn, we forecast a runway into H1 2027. On the opera
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.